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MODULATION OF ATP-SENSITIVE POTASSIUM CHANNEL ACTIVITY BY ATP-BINDING 
CASSETTE TRANSPORTERS: A MODEL FOR CHANNEL REGULATION 
Tong-Yi Yao and Marie E. Egan. Department of Pediatrics, Yale University, School of Medicine, New 
Haven, CT. 
The aim of this study was to characterize the relationship between ATP-Binding Cassette (ABC) 
transporters and heterologous ion channels. Our hypothesis was that regulation of ATP-sensitive 
potassium channel activity by ABC transporters is through direct interactions dependent upon motifs 
specific to this superfamily. If the hypothesis is valid, it suggests that certain ABC transporters may be 
able to interact with numerous ion channels. Furthermore, if direct coupling of specific domains or residues 
on the ABC transporter and channel protein are necessary, mutations in either protein would disrupt this 
interaction, diminishing the ABC transporters ability to modulate channel activity. 
Using two-electrode voltage clamping, this study examined two ABC transporters, the cystic 
fibrosis transmembrane conductance regulator (CFTR) and the pancreatic beta cell high-affinity sulfonylurea 
receptor (SUR1), and their interactions with “associated” inwardly-rectifying ATP-sensitive potassium 
channels, the renal potassium channels (ROMK 1/Kirl.la and ROMK2/Kirl.lb) and the pancreatic 
potassium channel (BIR/Kir6.2). Expression of either ROMK1 (Kir 1.1a) or ROMK2 (Kiri.lb) alone in 
Xenopus oocytes resulted in barium-sensitive potassium currents with minimal to moderate sulfonylurea 
(glibenclamide) sensitivity. Coexpression of either CFTR or SUR1 with ROMK2 (Kiri.lb) greatly 
enhanced the sensitivity of the potassium currents to sulfonylurea. In contrast, neither the expression of 
CFTR or SUR1 with ROMK1 (Kiri.la) enhanced the effects of glibenclamide on potassium currents. In 
fact, the expression of CFTR with ROMK1 (Kiri.la) decreased the glibenclamide effect. These data 
suggest that the interaction of ABC transporters with ion channels is dependent upon characteristics of both 
subunits. 
Lastly, we examined the clinical impact of disrupting the interactions between ABC transporters 
and ATP-sensitive potassium channels in a case of familial hyperinsulinemic hypoglycemia of infancy 
(PHHI). In accordance with our above findings, coexpression of SUR1 with a BIR (Kir6.2) mutant 
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identified in an infant with PHHI failed to produce a potassium current, demonstrating that a nonfunctional 
BIR (Kir6.2) mutant resulted in a potassium channel that was nonfunctional. 
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1. Introduction 
1-1. ATP-Binding Cassette Transporter Superfamily 
1-1.1. The Typical ABC Transporter 
The ATP-binding cassette (ABC) transporters are a superfamily of over 100 
transmembrane proteins characterized by a highly conserved ATP-binding cassette, or 
nucleotide binding fold (NBF) (Higgins, 1992; Higgins, 1995). In general, their structure 
consists of four core domains—two transmembrane domains and two nucleotide-binding 
domains (Figure 1). In prokaryotes, the four domains exist more commonly as separate 
polypeptides while in eukaryotes they tend to exist as fused multidomain complexes. 
Whether expressed as separate polypeptides or as a multidomain protein, the 
transmembrane domains appear to associate with and anchor the two nucleotide-binding 
domains. Several bacterial transporters appear to have a highly conserved short sequence 
on a cytoplasmic loop of the transmembrane domain which may interact with the 
nucleotide-binding domains. Members of this superfamily function as selective active 
transporters or channels. ABC transporters may either export or import substrate; none, at 
present, demonstrate bidirectional transport. Substrates range from simple inorganic ions, 
sugars, and amino acids to more complex polysaccharides and proteins. 
While the ABC transporter superfamily is defined by the basic four domain 
complex described above, there is limited sequence conservation between different proteins 
in the family. The highest degree of sequence identity is found in the nucleotide-binding 
domains. No experimental data (NMR, crystallographic, microscopic) detailing the exact 
structure of ABC transporters is presently available. Computer-generated predictions based 
upon the amino acid sequence suggest that each transmembrane domain consists of multiple 
alpha-helical membrane-spanning segments with the N- and C- termini are usually present 
on the cytoplasmic side. Exceptions such as the sulfonylurea receptor whose N-terminus is 
extracellular do exist. Although a typical ABC transporter has six segments, significant 
' 
2 
variation in the number of alpha-helical membrane-spanning segments present in each 
transmembrane domain occurs. 
1 -1.1.1. Role of the Transmembrane Domains 
The transmembrane domains are believed to form the path for substrate transport 
and determine substrate specificity (Higgins, 1992; Higgins, 1995). As the proteins are 
involved in the transport of highly diverse substrates and as the amino acid residues 
responsible for specificity need not be adjacent on the primary sequence, the amino acid 
sequences of the transmembrane domains exhibit great variability when comparing between 
different proteins. However, sequence similarities that do exist between transporters do 
not necessarily translate into similarities in substrate specificity. When the two 
transmembrane domains present in each individual ABC transporter are compared there is 
generally greater sequence identity present. In ABC transporters with only a single 
transmembrane domain, it may function as a homodimer. Greater sequence identity is 
found between the two distinct transmembrane domains of a single ABC transporter 
suggesting they may function together as a pseudodimer. 
1-1.1.2. Role of the Nucleotide-Binding Domains 
The highly hydrophilic nucleotide-binding domains reside on the cytosolic side of 
the membrane where their nucleotide binding folds interact with cytosolic nucleotides 
(Higgins, 1992; Higgins, 1995). These domains typically couple the energy of ATP 
hydrolysis to the transport of substrates across the membrane perhaps through 
conformational changes affecting the transmembrane domains. There is a high degree of 
sequence conservation in these domains between ABC transporters with up to 30-50% 
sequence identity depending on the proteins compared. Greater sequence identity is 
generally present between the two nucleotide-binding domains of a single transporter. This 
sequence identity includes the Walker A and Walker B motifs which are responsible for 
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interacting with the phosphates of nucleotides and associated with many other nucleotide¬ 
binding proteins. The presence of both nucleotide-binding domains is necessary for the 
function of the protein; however, the two nucleotide-binding domains are not necessarily 
functionally equivalent. For example, in P-glycoprotein, mutations in either domain 
impacts adversely on transport activity. However, in cystic fibrosis many mutations in the 
first (or N-terminal) nucleotide-binding domain of CFTR result in a disease state but a 
mutation in the C-terminal nucleotide-binding domain does not appear to inhibit CFTR 
function (Welsh and Smith, 1993). 
1-1.2. ABC Transporters and Disease 
ABC transporters are now known to be involved in a variety of human diseases 
(Table 1) ranging from cystic fibrosis (CF) and persistent hyperinsulinemic hypoglycemia 
of infancy (PHHI), which are our focus in these studies, to other recessively inherited 
diseases such as X-linked adrenoleukodystrophy, Zellweger syndrome, and Stargardt 
macular dystrophy as well as multifactorial diseases such as noninsulin-dependent diabetes. 
In addition, ABC transporters affect the course of human disease by conferring 
chemotherapeutic drug resistance to cancer cells as well as antibiotic resistance to a variety 
of infectious microorganisms. 
1-1.3. ABC Transporters as Channel Regulators 
Studies have suggested that ABC transporters may interact with heterologous ion 
channel proteins regulating their activity (Higgins, 1995). This regulatory function may be 
as an extension of their intrinsic transporter or channel functions or a result of either direct 
or indirect interactions with these other channel proteins. Understanding how they function 
as channel regulators may give insight into the pathophysiology of the diseases associated 
with ABC transporter dysfunction and may provide new targets for treatment of the disease 
process. 
' 
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1-1.3.1. Mechanisms of Channel Regulation 
Four major models of regulation above the level of gene expression have been 
proposed to explain the mechanism by which ABC transporters may regulate other channel 
proteins (Figure 2) (Higgins, 1995). The first model assumes that a substrate (X) 
transported by the ABC protein acts as regulatory molecule to modulate channel activity in 
an autocrine fashion. In this model, the ABC protein’s regulation of another channel is a 
consequence of its intrinsic transporter function. The second model proposes direct 
interactions between the ABC transporter and the channel protein as the basis of modulation 
of channel activity. These could involve protein-protein interactions or the formation of an 
ABC transporter-channel protein complex. The third and fourth models are of indirect 
interactions not associated with the ABC protein’s transporter function; one looks upon the 
ABC transporter as a facilitator of increased insertion of channel proteins into the 
membrane while the other model postulates the coupling of the ABC transporter with 
intermediate protein molecules, possibly cytoskeletal components, thereby effecting the 
channel protein. 
Our studies focus upon the direct model of channel regulation. Direct interactions 
appear to explain how CFTR and SUR1 function as channel regulators. More specifically, 
the regulation of channel activity appears to be dependent upon the presence of specific 
motifs of ABC transporters, such as the NBFs (McNicholas et al., 1997). 
1-1.3.2. Multidrug Resistance Gene Product P-glvcoprotein 
P-glycoprotein is responsible for the multidrug resistance of cancers to 
chemotherapeutic drugs. P-gp functions as an active exporter of hydrophobic compounds 
including chemotherapeutic drugs. When overexpressed in cancer cells P-gp confers upon 
them multidrug resistance by reducing the cytoplasmic concentrations and cytotoxicity of 
the chemotherapeutic drugs. The energy to pump the drugs out of the cell is derived from 
4 
5 
ATP hydrolysis. P-gp expression is also associated with increased volume-activated Cl 
channel currents suggesting that it may be a multifunctional protein with an additional 
physiological function as a regulator of epithelial cell volume (Gill et al., 1992; Valverde et 
ah, 1992). The volume-activated Cl channel appears to be sensitive to osmotic gradients. 
P-gp appears to affect the channel activation through altering this sensitivity as well as 
imposing a dependency on protein kinase C. 
1-1.4. Promiscuity of ABC Transporters 
Studies have suggested that ABC transporters may be able to substitute for other 
members of the family in their interactions with heterologous proteins (Ammala et ah, 
1996). Whether this ability to substitute for other members of the family is a consequence 
of similarities in motifs allowing for equivalent direct coupling of ABC transporters with 
channel proteins is unclear. Another possibility is that ABC transporters capable of 
exporting or importing similar substrates may substitute for one another. For example, 
such a relationship was found to exist between two ABC transporters, P-gp and STE6 
which is responsible for exporting a-factor mating peptide in yeast (Raymond et ah, 
1992). When the mouse mdr3 gene which produces P-pg was expressed in a yeast cell 
with an ste6 deletion, the cell regained its ability to export a-factor. In this study, a 
mutation known to affect the activity of P-gp was then introduced into the mdr3 gene. 
Coexpression of this mutant with the STE6 deficient yeast cell did not restore function. 
Studies done coexpressing SUR1 with inwardly rectifying potassium channels (Kirl.la and 
Kjr6.1) other than BIR (Kir6.2) suggest that it is able to interact with multiple Kjr channels 
and confer sulfonylurea sensitivity (Ammala et ah, 1996). 
1-2. Cystic Fibrosis Transmembrane Conductance Regulator 
The cystic fibrosis transmembrane conductance regulator (CFTR) is a somewhat 
atypical ABC transporter. Unlike the vast majority of ABC transporters, CFTR functions 
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as a chloride channel not as a transporter and possesses a five domain structure—two 
transmembrane domains, two nucleotide-binding domains, and an additional regulatory R- 
domain which appears to block the channel pore (Figure 3) (Fuller and Benos, 1992; 
Riordan, 1993; Tsui, 1995; Davis et al., 1996). Phosphorylation of this R-domain by a 
cyclic AMP-dependent protein kinase A (PKA) is required for channel activation. 
Maintenance of channel activity requires the continued presence of ATP at the NBFs. In 
addition, there appear to be other phosphorylation sites which may modulate channel 
kinetics and activity as well. 
1-2.1. Role in Regulation of Respiratory Secretions 
Normal function of CFTR appears important for effective mucociliary clearance, the 
mechanism by which inhaled foreign matter are removed from the lungs. Respiratory 
secretions are critical in the maintenance of mucociliary clearance (Welsh, 1988). The two 
components of the system are the cilia of the epithelial cells and the respiratory fluids. The 
respiratory fluids can be conceived as a bilayer with a discontinuous mucus layer, or gel 
phase, overlying a periciliary fluid layer, or sol phase, in which the cilia are immersed. 
The mucus layer serves to trap inhaled particles whereas the periciliary fluid provides a 
watery medium in which the cilia can beat freely. The tips of the cilia are in contact with 
the mucus facilitating its movement along with the foreign matter towards the larynx. 
A number of features of the airway epithelium are critical for the maintenance of 
electrolyte and water transport necessary to ensure the appropriate quantity and composition 
of the periciliary fluid as well as the quality of the mucus. The airway epithelial cells are 
polar with distinct apical and basolateral surfaces. The ciliated apical membrane facing the 
lumen and the basolateral membrane facing the interstitial space differ in the types of 
receptors, transporters, and channels present. The two cell surfaces are further 
differentiated by the presence of tight junctions joining the epithelial cells along their apical 
surfaces producing a continuous barrier between the luminal and interstitial spaces. This 
' 
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barrier serves as a semipermeable membrane allowing regulated solute and water movement 
with net secretion or absorption. Two pathways of movement across the airway epithelium 
exist—a paracellular pathway between cells at the tight junctions and a cellular pathway 
through the epithelial cells themselves. 
The interplay between chloride secretion and sodium absorption determines whether 
fluid is secreted or absorbed by the epithelium, respectively (Welsh, 1988). Whether one 
or the other process predominates is dependent upon the neurohumoral environment and 
the anatomical region of the airway. Both, however, are dependent upon cellular and 
paracellular pathways. Chloride secretion “begins” with chloride entry across the 
basolateral membrane coupled to sodium entry. This is an electrically neutral cotransport 
process in which chloride moves against its electrochemical gradient while sodium moves 
down its electrochemical gradient. Whether the cotransport process involves a Na7Cl 
cotransporter or a Na7K72Cl" cotransporter is dependent upon cell type. The chloride then 
moves passively across the apical membrane down it electrochemical gradient through 
chloride channels. Some of the apical chloride channels involved are the cystic fibrosis 
transmembrane regulator (CFTR) chloride channel, the outwardly rectifying chloride 
channel (ORCC), and the calcium-activated chloride channel. The basolateral Na7K+ 
pump, or Na+,K+-ATPase, is responsible for maintaining the low intracellular sodium 
concentrations and negative intracellular voltage necessary for this chloride secretion. The 
intracellular potassium accumulated through the Na+,K+-ATPase as well as the Na7K72Cl' 
cotransporter passively leaves the cell through a basolateral potassium channel. This 
basolateral potassium channel also serves to maintain a negative intracellular voltage 
conductive to chloride leaving the cell at the apical membrane. The net result of the 
depolarizing transport of chloride across the apical membrane and the hyperpolarizing 
transport of potassium across the basolateral membrane is a transepithelial voltage which 
drives the paracellular flow of sodium from the interstitial space to the lumen (Figure 4), 

Sodium absorption “begins” with sodium entry across the apical membrane through 
sodium channels down its electrochemical gradient. The Na+,K+-ATPase then pumps 
sodium against its electrochemical gradient across the basolateral membrane. 
This balance of secretion and absorption impacts upon mucociliary clearance 
through two mechanisms—the hydration of the mucus layer and the depth of the periciliary 
fluid layer. Airway mucus is produced and secreted primarily by the submucosal glands; 
however, additional secretory products of goblet cells, ciliated cells, and Clara cells also 
contribute to its composition. As fluid secretion decreases when chloride secretion 
decreases or sodium absorption increases, the mucus and periciliary layers become 
dehydrated making the mucus more viscous and the periciliary layer too shallow for 
effective ciliary beating. Likewise, fluid result in a periciliary layer which is too deep 
preventing the cilia tips from contacting with and moving the mucus layer. 
1-2.2. Role in Cystic Fibrosis 
Cystic Fibrosis (CF) is a common genetic disease affecting the Caucasian 
population with a frequency of approximately one in 2500 live births. This autosomal 
recessive disease affects multiple organ systems including the respiratory, gastrointestinal, 
and reproductive systems. The underlying defect in CF is in the gene encoding CFTR 
located on chromosome 7 (Riordan et al., 1989; Rommens et al., 1989). Although the 
gene was not identified until 1989 by Riordan et ah, studies by Quinton and Knowles and 
Boucher during the early 1980s had already demonstrated the primary defect as a decrease 
in chloride permeability. The characteristic clinical findings of mucus plugging and 
infection in the airways, pancreatic insufficiency, and elevated sweat chloride 
concentrations are a result of this alteration of chloride permeability in secretory epithelial 
cells in the airways, exocrine pancreas, and sweat glands. Recently, Smith et ah postulated 
that this alteration in chloride and sodium permeability may lead to changes in airway 
surface fluid which, in turn, may alter the natural defenses of the lung by inactivating salt- 
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sensitive peptides, such as defensins (Smith et al., 1996). Currently, the progressive 
airway disease—decreased mucociliary clearance, mucus plugging, bronchiectasis, and 
ultimately respiratory failure—is the major cause of morbidity and mortality in CF patients 
(Fuller and Benos, 1992; Riordan, 1993; Tsui, 1995; Davis et al., 1996). 
Mutations resulting in the loss or reduction of CFTR’s chloride conductance can be 
classified into four categories dependent on where they impact on the “pathway” of CFTR 
production and function following insertion into the cell membrane (Welsh and Smith, 
1993). This “pathway” can be conceptually divided into four areas: protein production, 
protein processing/trafficking, channel regulation/activation, and chloride conduction 
(Table 2). Defects in channel regulation/activation can also be conceptualized as defects 
within the nucleotide binding domains, specifically the NBF, as they are intimately 
involved in channel regulation/activation. Likewise, defects in chloride conduction appear 
to be localized to the transmembrane domains which are postulated to form the channel 
pore. The most common mutation is a single amino acid deletion of phenylalanine at 
position 508 (AF508). The AF508 mutation results in defective protein 
processing/trafficking. The AF508 protein appears to be incorrectly folded and therefore 
not trafficked to the Golgi apparatus where it would otherwise be fully glycosylated and 
subsequently transported to the cell membrane for insertion. 
1-2.3. CFTR as Regulator of Heterologous Channel Activity 
CF-affected cells exhibit a number of ion transport abnormalities—increased 
sodium absorption, abnormal regulation of outwardly rectifying chloride channels 
(ORCCs), and increased calcium-activated chloride channel activity—which can not be 
explained solely by CFTR’s function as a chloride channel. CFTR appears to be a cAMP- 
dependent regulator of amiloride-sensitive epithelial sodium channels (ENaC) (Stutts et al., 
1995; Mall et al., 1996). The mechanism of this interaction while presumed to be direct, 
however, is unclear. CFTR regulation of ORCCs, which are present in the apical 
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membranes of airway epithelium, may involve the release of ATP to the extracellular 
surface (Gabriel et al., 1993; Jovov et al., 1995; Schwiebert et ah, 1995). Whether the 
ATP is transported by CFTR, by an associated channel regulated by CFTR, or by another 
mechanism is unclear. What is evident is that in CF-affected cells the normal regulation of 
ORCCs by PKA and ATP is defective and that expression of wild type CFTR in these 
same cells corrects the defect (Egan et ah, 1992). The increase in calcium-activated 
chloride channel activity appears to be a result of up-regulation (Grubb et ah, 1994). 
Correction of the calcium-activated chloride channel activity and ENaC activity when CF- 
affected cells are transfected with CFTR supports the notion that CFTR is critical to the 
regulation of these channels. 
1-2.3.1. CFTR and Potassium Channels 
There is also evidence that CFTR can modify KATP channel activity. The ROMK 
family of apically-located renal KATP channels is a subgroup of the inwardly rectifying 
potassium (Kir) channel superfamily (Hebert and Ko, 1994; Zhou et ah, 1994; Boim et ah, 
1995). Kjr channels maintain the membrane potential (Em) of numerous excitable and non- 
excitable cells near the potassium reversal potential (EK) (Fakler and Ruppersburg, 1996; 
Ackerman and Clapham, 1997). KATP channels within the apical membrane of distal 
nephron segments of the kidney play a major role in potassium homeostasis. Multiple 
isoforms of ROMK have been identified. ROMK2 (Kiri.lb), an alternate splice isoform 
with 19 fewer amino acid residues present on the N-terminus than ROMK1 (Kiri.la), 
maintains many of the characteristics of native renal KATP channels; however, it lacks the 
same sensitivity to sulfonylureas such as glibenclamide. Coexpression of CFTR, which is 
present in the nephron, with ROMK2 (Kiri.lb) appears to confer this glibenclamide 
sensitivity to the KATP channel (McNicholas et al., 1996). As this effect was not found to 
be dependent upon PKA and ATP, active transport by CFTR does not appear to be 
necessary, suggesting a direct interaction between CFTR and ROMK. A recent study 

demonstrated CFTR as localizing to the apical membrane of the cortical collecting duct 
where ROMK2 (Kiri.lb) has previously been found (Todd-tura et al., 1996). In light of 
these studies, a role for CFTR in the regulation of ROMK channel activity appears 
possible. 
This ability of CFTR to regulate KATP channel activity is also present in another 
member of the ABC transporter superfamily, SUR1. 
1-3. Sulfonylurea Receptor 
The complementary DNA for SUR1 was first cloned in 1995 by Aguilar-Bryan et 
al. classifying it as a member of the ABC transporter family because it showed significant 
sequence similarities to other members of the superfamily such as P-gp and CFTR 
(Aguilar-Bryan et al., 1995). Two nucleotide binding folds with Walker A and B 
consensus sequences were identified. SUR1, however, has unique structural 
characteristics. Although a multidomain protein like many other eukaryotic ABC 
transporters, it possesses nine and four segment transmembrane domains alternating with 
the two nucleotide-binding domains. Its N-terminus is also located extracellularly. 
SURl’s role in pancreatic beta cell KATP channel activity was initially unclear because, as a 
member of the ABC transporter superfamily, it could function either as the potassium 
transporter itself or as the regulator of a separate potassium channel subunit. Expression of 
SUR1 alone resulted in no channel activity, suggesting that coupling with BIR (Kir6.2) 
was necessary for a functional KATP channel. 
1-3.1. Role in Regulation of Glucose Homeostasis 
The pancreatic beta cell ATP-sensitive potassium (KATP) channel is postulated to be 
a complex of two subunits, SUR1 and BIR (Kir6.2) (Figure 5) (Philipson and Steiner, 
1995; Inagaki et al., 1995). SUR1 appears to serve as the regulator of channel activity 
while BIR (Kir6.2) forms the channel pore. Studies in which expression of either SUR1 
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or BIR (Kir6.2) alone did not yield K+ currents above the endogenous levels of the cell 
system support the theory that they act as a functional unit (Aguilar-Bryan and Bryan, 
1996; Gribble et al., 1997). SUR1 was originally of clinical interest because of the use of 
sulfonylureas as oral hypoglycemics to stimulate insulin secretion from pancreatic beta cells 
in the treatment of non-insulin dependent diabetes mellitus (NIDDM). 
In physiologic regulation of glucose homeostasis, the KATP current (IKAXP) sets the 
resting membrane potential for the pancreatic beta cell (Aguilar-Bryan and Bryan, 1996). 
Increases in the glucose concentration translate into an increase in the cytosolic ATP to 
ADP ratio which closes the KATP channel and blocks the outflow of potassium. The 
subsequent depolarization of the membrane results in the activation of voltage-dependent L- 
type calcium channels. The calcium influx triggers exocytosis and insulin release (Figure 
6). Sulfonylureas such as glibenclamide bring about insulin release through inhibition of 
the Katp channel. 
1-3.2. Role in Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) 
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is a rare autosomal 
recessive disorder of glucose metabolism characterized by recurrent episodes of profound 
hypoglycemia associated with abnormal regulation of insulin secretion (Aguilar-Bryan and 
Bryan, 1996; Permutt et al., 1996). These episodes of severe hypoglycemia can present in 
the early newborn period or as late as several months of age. In all cases, whether the 
plasma insulin levels are high normal or grossly elevated, there is inappropriately high 
levels of insulin during hypoglycemia. In order to avoid hypoglycemia, patients require 
parenteral glucose, often in high doses. Current treatment strategies include pharmacologic 
interventions such as diazoxide or a somatostatin analog. Octreotide, as well as surgical 
options such as partial pancreatectomy for refractory hyperinsulinism. Although the 
disease was described as early as 1953 by McQuarrie and has also been referred to as 
familial hyperinsulinism and pancreatic nesidioblastosis, the molecular basis was not 
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elucidated until 1995 when Aguilar-Bryan et al. cloned the gene and Thomas et al. reported 
the first findings of mutations in SUR1 in families with PHHI (Aguilar-Bryan et al., 1995; 
Thomas et al., 1995). PHHI has an incidence of one in 50,000 live births in the western 
European population. In populations such as the Saudi Arabians where there is a high 
percentage of consanguineous matings, the incidence is much higher, approximately one in 
2500 live births. The existence of such families with PHHI facilitated mapping the gene to 
chromosome 11 p 15.1 by linkage analysis. Both SUR1 and BIR (Kir6.2) are clustered on 
chromosome 11 p 15.1 with the BIR (Kir6.2) gene immediately 3’ of the SUR1 gene. 
Recent studies have attributed patient cases to mutations in the first and second nucleotide¬ 
binding fold regions of SUR1 as well as to mutations in BIR (Kir6.2) (Thomas et al., 
1996). In some cases these mutations led to truncated proteins while in others they 
disrupted RNA processing. Both nucleotide-binding domains, however, appear to be 
necessary for nonnal channel activity. It appears that mutations in either SUR1 or BIR 
(Kir6.2) could result in continuous membrane depolarization and subsequent continuous 
secretion of insulin. 
Mutations in SUR1 have also been implicated in NIDDM suggesting that the BIR 
(Kir6.2)-SUR1 complex plays a pivotal role in the regulation of insulin secretion and 
maintenance of glucose homeostasis (Nestorowicz, et al., 1996). 
1-3.3. SUR1 as Regulator of Heterologous Channel Activity 
SUR1 has been demonstrated to interact with numerous KATP channels other than 
BIR (Kir6.2), affecting their regulation by sulfonylureas (Ammala et al., 1996). These 
studies have suggested that interactions between ABC transporters and certain ion channels 
may be promiscuous. 
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2. Statement of Purpose 
Our hypothesis is that ABC transporters are multifunctional proteins that act not 
only as active transporters or channels, but also as regulators of heterologous channels. 
More specifically, we hypothesize that ABC transporters regulate heterologous channel 
activity via direct interactions dependent upon motifs specific to ABC transporters. If direct 
coupling of specific domains or residues on the ABC transporter and channel protein is 
necessary, mutations in either protein would disrupt this interaction diminishing the ABC 
transporters ability to modulate channel activity. To examine the possibility of ABC 
transporters substituting for one another in their interactions with heterologous channel 
proteins, studies were done looking at possible relationships between ABC transporters 
(CFTR and SUR1) and KATP channels (ROMKl/Kirl.la, ROMK2/Kirl.lb, and 
BIR/Kir6.2). In addition, preliminary studies examining the interactions between SUR1 
(wild type) and BIR/Kir6.2 (wild type and mutant) were performed. Together, these 
experiments will help determine the structure-function relationship responsible for the 
interaction between ABC transporters and channel proteins and elucidate what regions of 
the ABC transporters are necessary for channel regulation. 
All two-electrode voltage clamp studies were performed upon mRNA-injected 
Xenopus oocytes. More specifically, the following questions were addressed in this study: 
1) Do mutations in specific domains of CFTR impair its ability to interact with the channel 
protein ROMK2 (Kiri.lb) thus altering the channel activity or glibenclamide 
sensitivity of the coexpressed peptides? 
2) Can SUR1 substitute for CFTR in the CFTR/ROMK interaction? 
3) Do alterations in ROMK affect its ability to interact with CFTR thus altering the channel 
activity or glibenclamide sensitivity of the coexpressed peptides? 
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4) Do mutations in specific domains of either SUR1 or BIR (Kir6.2) impair their ability to 
interact thus altering the glibenclamide sensitivity of the coexpressed peptides? 
H 
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3. Methods 
3-1. Xenopus Oocyte Expression System 
The Xenopus laevis oocyte expression system was first introduced in 1971 by Gurdon 
as a means to study the control of gene expression (Gurdon et al., 1971). In 1982, Miledi 
et al. demonstrated that injection of exogenous mRNA into the cytoplasm resulted in 
expression of ion channels and receptors. As stage V and VI oocytes possess adequate 
protein translation and modification machinery, it has proven to be a reliable expression 
system for the study of ion channels and transporters (Sherman-Gold, 1993). The oocytes 
are readily harvested through partial ovariectomy through a small incision in the frog’s 
abdominal wall. With an adequate recovery period, frogs can be operated upon multiple 
times. 
Oocytes develop in a six stage process from I to VI. Stage V and VI oocytes are 
approximately 1-1.2 mm and possess two distinct poles—a darker-colored animal pole and 
a lighter, cream-colored vegetal pole. The vitelline membrane, a glycoprotein matrix which 
provides structural support in maintaining the oocytes’ spherical shape, envelops each 
individual oocyte. An additional layer of follicular cells surrounds the vitelline membrane. 
These follicular cells are electrically coupled to one another and to the oocyte by gap 
junctions. As these follicular cells can interfere with recordings, they are removed prior to 
RNA injection and voltage or patch clamping. The collection of oocytes, follicular cells, 
connective tissue, and blood vessels constitutes an ovarian lobe. 
3-1.1. Harvesting of Xenopus Oocytes 
A single frog (Nasco, Xenopus Express, or Xenopus One) was selected for oocyte 
harvest through partial ovariectomy. Care was taken to select a frog whose prior surgical 
incisions have been allowed to heal at least 3 to 4 weeks. The frog was anesthetized in a 
0.17% tricaine (3-aminobenzoic acid ethyl ester, methane sulfonate salt, Sigma) bath pH 
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7.4 at room temperature for approximately 10-15 minutes until it was unresponsive when 
held in the supine position. The frog was then placed in the supine position on a layer of 
Saran Wrap over a tray of ice. These measures were taken to ensure clean conditions, 
reduce risk of frostbite, and maintain moisture levels in the frog skin. Sterile gloves were 
used throughout the procedure. All surgical instruments were cleaned with 70% isopropyl 
alcohol prior to each use and periodically autoclaved as well. Care was taken to avoid 
contamination as much as possible. A small horizontal incision approximately 1 cm wide 
was made in the abdomen wall, lateral to the midline. Three to four ovarian lobes were 
gently removed from the abdominal cavity using forceps and scissors. These lobes were 
placed in Ca2+-free ND96 solution. The wound was closed in two layers. The muscle and 
fascial layers were closed together with 5-0 chromic gut (Ethicon). The skin was closed 
with 6-0 ethilon (Ethicon). The frog was then placed into a clean individual tank for a few 
hours to recover from the anesthesia and surgery prior to return to the general tank. 
3-1.2. Preparation. Selection, and RNA Injection of Xenopus Oocytes 
The ovarian lobes were gently dissected into smaller sections using forceps. In 
order to separate the oocytes from the connective tissue, blood vessels, and follicular cells 
which together form the lobe, they were treated with collagenase A (Sigma or Boehringer 
Mannheim) at a concentration of 2 mg/ml of Ca2+-free ND96 and gently agitated for 1 to 
1.5 hours at room temperature. Any remaining follicular cells were manually removed with 
forceps. After incubation in collagenase, the oocytes were washed with Ca2+-free ND96 to 
stop the digestion process and then washed with the more isotonic Ca2+-plus ND96. 
Oocytes were stored in Ca2+-plus ND96 supplemented with 450pM gentamicin (Gibco) and 
2.5mM sodium pyruvate (Boehringer Mannheim) in a 18°C incubator. An alternate oocyte 
media based upon half-strength Leibovitz L-15 Medium (Gibco BRL) and 5mM Hepes 
supplemented with penicillin/streptomycin (500U/ml of media) and 50pg/ml (500pM) 
gentamicin was used as well. 
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Oocytes were selected on the basis of maturity (stage V and VI) and uniformity in 
the color of the animal and vegetal poles with a clear boundary between the two. Care was 
taken to examine the oocytes daily and to remove any cells with areas of decoloration, a 
speckled appearance, or outpouching of the membranes—all signs of a dying cell. The 
storage media was also changed every other day. 
Care was taken throughout the injection protocol to minimize contamination by 
RNases. Gloves were worn at all times when handling the mRNA. Disposable 
micropipettes (Drummond Microcaps, 64mm length, 6 pi) were pulled using a pipette 
puller (Narishige). The end of the tip was clipped under the microscope for an opening 
diameter of approximately 5pm. The mRNA solution consisted of either a single type of 
mRNA or two types mixed together prior to injection. Concentrations of the mRNAs were 
0.03 or O.lpg/pl for ROMK1 (Kiri.la), 0.03 or O.lpg/pl for ROMK2 (Kiri.lb), 
0.5pg/pl for CFTR, 0.5 to 0.8pg/pl for SUR1, 0.4 to 0.6pg/pl for BIR (Kir6.2), and 
0.5pg/pl for A9 (a BIR/Kir6.2 mutant). For injection, the mRNA solution was transferred 
to a RNase-free surface. The injection pipette was attached to a hand-driven, coarse 
manipulator (MK1 Manipulator, Singer Instruments) which was connected to a pneumatic 
injector (Inject+Matic, Geneve). The droplet of mRNA solution was aspirated into the 
pipette as quickly as possible to avoid excessive evaporation of the microliter volumes. 
Pressure and time of injection were adjusted to ensure that approximately 50nl aliquots 
were injected into each oocyte. Exogenous mRNA was injected preferably into the vegetal 
pole as the voltage clamp microelectrodes were inserted into the animal pole during 
experiments. 
3-2. Molecular Biology 
3-2.1. Bacterial Cell Transformation and Plasmid Purification 
Subcloning efficiency DH-5a or DM1 competent Escherichia coli cells were used 
for bacterial cell transformation. Approximately 500ng of plasmid DNA was added to 
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lOOjal of competent cells in a chilled microcentrifuge tube and incubated on ice for 30 
minutes. The mixture was heat shocked for 45 seconds at 37°C before being placed back 
on ice for 2 minutes. 0.9ml of Luria-Bertani (LB) media without antibiotics (ampicillin) 
was added to the microcentrifuge tube and then the E. coli/plasmid DNA mixture was 
grown on a shaker for 1 hour to overnight at 37°C. A series of dilutions of the 
transformation growup was plated on LB-ampicillin (100 pg/ml) agar plates and then 
incubated at 37°C overnight. Ampicillin was used to apply selection pressure ensuring that 
only daughter cells containing the plasmid of interest remain. A single bacterial colony 
from the LB-ampicillin plates was used for growup. Depending on the plasmid purification 
kit being used (Qiagen Midi-prep, 5 Prime-^3 Prime BIGprep, or 5 Prime—>3 Prime 
PERFECTprep), the single colony was inoculated in 5-60 ml of LB buffer plus ampicillin 
(100 pg/ml) and shaken overnight at 37°C. Alternate “richer” growth media such as 
Terrific Broth (TB) can be used as well. Plasmid purification was performed per the 
protocols provided in the various kits. 
The basic principle of plasmid purification is lysis of bacterial cells followed by 
purification and isolation of supercoiled plasmid DNA. The amount of culture volume 
processed in each sample is dependent upon the cell density. If the volume is too large 
there may be inefficient cell lysis, overload of the binding column, and a high lysate 
viscosity. Care must be taken to mix the lysate thoroughly but gently to avoid shearing of 
the bacterial genomic DNA whose fragments may contaminate the plasmid DNA. The 
lysate is applied to a resin column where the plasmid DNA is selectively bound. The 
column is washed with buffers to remove RNA and protein contaminants. The plasmid 
DNA is then eluted from the column, desalted, concentrated, washed, and finally 
resuspended in RNase-free H20. The plasmid DNA is stored at -20°C. 
' 
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3-2.2. Linearization of cDNA 
Basic principles of setting up a restriction reaction include: 1) choosing an 
appropriate restriction enzyme, 2) determining the concentration of the enzyme, 3) 
determining the minimum amount of enzyme required for effective linearization, 4) 
determining the concentration of the plasmid DNA, 5) deciding upon the amount of DNA to 
be linearized, 6) deciding upon the desired excess of enzyme, and 7) calculating the amount 
of buffer and other solutions needed for optimal action of the specific restriction enzyme. 
The restriction reaction is incubated for 1.5 to 2 hours or overnight at 37°C. After an 
appropriate period of incubation, proteinase K and sodium dodecyl sulfate (SDS) are added 
to halt the restriction reaction, digest the remaining restriction enzyme, and eliminate RNase 
contamination. Care is taken from this point to remain RNase-free. The plasmid DNA is 
extracted with a 25:24:1 (vol.) phenol:chloroform:isoamyl alcohol mixture. The phenol 
serves to denature proteins in the nucleic acid solution. Subsequent chloroform extractions 
serve to remove residual phenol from the aqueous phase containing the linearized DNA. 
Together, these extractions also remove residual SDS which may interfere with in vitro 
transcription reactions. Ammonium acetate and ethanol are added to precipitate the nucleic 
acid and to reduce coprecipitation of unincorporated nucleotides. The precipitate is washed 
in ethanol to remove residual salts and ethylenediamine-tetraacetic acid (EDTA) which may 
later interfere with bacteriophage RNA polymerases. Finally, it is microcentrifuged to 
pellet the DNA and allowed to dry prior to resuspension of the linearized DNA in RNase- 
free dH20 and stored at -20°C. 
Human SUR1 subcloned into PCR3.1 or Bluescript M13 was provided by Dr. 
Pamela Thomas (University of Michigan, Ann Arbor). SUR1 was linearized using Xba I 
restriction enzyme (New England BioLabs) for cleavage at the carboxy-terminal (3’) end. 
Human BIR (Kir6.2) subcloned into PCR2.1 was provided by Dr. Pamela Thomas 
(University of Michigan, Ann Arbor). BIR (Kir6.2) was linearized using Spe I restriction 
enzyme (New England BioLabs). 
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Human CFTR subcloned into pBQ4.7 was provided by Drs. William B. Guggino 
and Erik M. Schwiebert (Johns Hopkins University, Baltimore and University of Alabama 
Birmingham, Birmingham). CFTR was linearized using EcoR V restriction enzyme (New 
England BioLabs). 
Human ROMK2 (Kiri.lb) subcloned into pSportl was provided by Drs. Gerhard 
Giebisch (Yale University, New Haven) and Steven C. Hebert (Vanderbilt University, 
Nashville). ROMK2 (Kiri.lb) was linearized using Not I restriction enzyme (New 
England BioLabs). 
3-2.3. In Vitro Transcription of Capped mRNA 
In vitro transcription was performed using the Ambion MEGAscript or mMessage 
mMachine kits to produce capped mRNA for Xenopus oocyte injection purposes. Capping 
of mRNA allows for more efficient translation. Each kit includes the appropriate 
bacteriophage RNA polymerase (SP6, T7, or T3) as well as transcription buffer, enzyme 
mix, ribonucleotide solutions, DNase, transcription stop mix, and lithium chloride 
precipitation solution. 
The general principles of in vitro transcription involve the assembly of a 
transcription reaction which consists of linearized template DNA, ribonucleotides, cap 
analog, RNA polymerase, and transcription buffer. This transcription reaction is incubated 
at 37°C for 1 to 6 hours depending on the length of the transcript and the transcription kit 
being used. DNase 1 is added to stop transcription and degrade the template DNA. The 
mRNA is then precipitated by lithium chloride and washed by ethanol to remove 
unincorporated nucleotides. An alternative method is phenol/chloroform extraction 
followed by precipitation with ammonium acetate and isopropyl alcohol, a process which 
may be more effective in removal of proteins. Both methods end with centrifugation to 
pellet the mRNA, careful removal of the supernatant, and resuspension of the mRNA in 
RNase-free dH2Q. The mRNA was stored at -80°C. 
% 
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3-2.4. Verification of cDNA and mRNA by Gel Electrophoresis 
Care was taken to verify that the appropriate plasmid DNA had been produced 
during the bacterial growup and subsequent plasmid purification process by 1% agarose gel 
electrophoresis. Prior to extraction and purification of the linearized cDNA, gel 
electrophoresis was repeated to confirm successful linearization of the cDNA in the 
restriction reaction. As the mRNA produced by in vitro transcription is sensitive to RNases 
present in the environment, the quality of the mRNA is confirmed by gel electrophoresis 
prior to injection into oocytes. 
3-3. Two-Electrode Voltage Clamp Technique 
3-3.1. Theory 
Voltage clamp studies are based upon the principle of setting the membrane voltage 
and measuring the transmembrane current require to maintain that voltage (Sherman-Gold, 
1993). By clamping the voltage, the capacitive spike/transient is effectively limited to the 
brief time required to charge the membrane prior to changing the membrane to the set 
voltage. In doing so, the current effectively becomes proportional to the membrane 
conductance which is determined by the number of open channels. 
The intracellular microelectrodes used in two-electrode voltage clamping consist of 
a AgCl-coated Ag wire placed within a solution-filled glass micropipette. To reduce 
electrode resistance concentrated KC1 solution can be used. While such a solution also 
allows more accurate measurement of resting potential, it has the disadvantage of 
potentially altering the normal ion concentrations within the cell as a result of the fluid 
connection which exists between the electrode and the cell interior. Smaller pipette tip 
diameters would minimize such mixing; however, the concomitant increase in the resistance 
of the pipette becomes the limiting factor as it impacts on current passing ability and noise. 
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Selection of the glass used for the intracellular microelectrodes is dependent upon 
the magnitude of currents to be measured, the degree of “acceptable” noise, and the need to 
generate a tight seal. Thickness of the walls determines the degree of electrical noise 
generated and the bluntness at the tip. Other properties of the glass to consider are the 
temperature required to soften the glass and the noise that it will generate. For the purposes 
of two-electrode voltage clamping, sharper tips on the standard intracellular microelectrodes 
are required in order to penetrate the cell membrane. For patch clamp experiments, glass 
selection is more critical in order to achieve gigaohm seals. Our micropipettes were pulled 
in a vertical multiple stage Narishige pipette puller. 
Voltage clamping oocytes poses two unique challenges due to the size of the cell 
and its relative efficiency in expressing injected mRNA. In stage V and VI oocytes, the 
surface area, assuming an ideal spherical shape and not taking into account invagination of 
the membrane, is on the order of 106 pm2. As capacitance is proportional to area, the 
current necessary to charge up the membrane prior to changing the membrane potential is 
significant and consequently the time to charge the membrane is longer. In addition, the 
large currents which may result from efficient channel protein expression and insertion into 
the cell membrane may pose problems in controlling the voltage. To address the problem 
of such a large membrane capacitance, lower resistance electrodes can be utilized. 
Appropriate shielding of the electrodes to reduce capacitive coupling also improves the 
speed at which voltage changes can be achieved. 
3-3.2. Channel Recording and Analysis 
Data was acquired through the GeneClamp 500 (Axon Instruments) with 
conversion of the continuous analog data into digital format through the Clampex program 
within the pCLAMP6 suite (Axon Instruments). The Clampex program set the membrane 
at various holding potentials while simultaneously recording the transmembrane current. 
At specified time points—one minute intervals for our experiments—a trial was completed 
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and the data acquired was saved to a data file. Data was viewed on a monitor (Gateway 
2000 Vivitron 1776). Recordings were exported to computer (Gateway 2000 P5-166) 
through the Clampfit program and then converted to spreadsheet format in Microsoft Excel 
for analysis. 
3-4. Protocol 
3-4,1. Rationale for Use of Potassium Channel Blockers and Openers 
A number of pharmacologic agents were used in the experiments including 
sulfonylureas, barium, diazoxide, and sodium azide. The sulfonylureas, oral 
hypoglycemics used in the treatment of NIDDM, are of interest in our studies because of 
the high sensitivity of SUR1 to these compounds as well as their interactions with CFTR, 
another member of the ABC transporter family. A variety of different sulfonylureas 
(glibenclamide, tolbutamide, etc.) are currently available. They are lipophilic molecules 
and appear to be effective in blocking KATP current from either side of the membrane, 
perhaps as a result of diffusion across the membrane. The other potassium channel blocker 
used in our experiments is barium. Barium has been demonstrated to block a variety of 
potassium channels (voltage-gated, inwardly rectifying, ATP-sensitive). This suggests that 
there may be similarity between the pore regions of these potassium channels. 
Diazoxide, a benzothiadiazine structurally similar to the sulfonylureas, is an 
effective opener of the potassium channel in pancreatic beta cells. It produces membrane 
repolarization and consequently inhibition of insulin secretion. It also appears to be 
effective from either side of the membrane and dependent upon both ATP and Mg2+ for its 
action. The exact mechanism by which diazoxide activates KATP channels is unclear. 
Sodium azide is a metabolic inhibitor of mitochondrial electron transport protein 
cytochrome and the F,/F0 ATPase. Sodium azide brings about a decrease in intracellular 
ATP levels which presumably allows for an activation of the BIR (Kir6.2)-SUR1 channel 
complex and subsequent potassium currents. 
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3-4.2. Protocol for ROMK-Coiniected Oocytes 
Two-electrode voltage clamp experiments measuring whole-cell currents and 
response to sulfonylureas were performed on Xenopus oocytes injected with ROMK1 
(Kiri.la) alone, ROMK2 (Kiri.lb) alone, ROMK1 (Kiri.la) plus CFTR or SUR1, and 
ROMK2 (Kir 1.1b) plus CFTR or SURl. Experiments were performed on days 2-6 post¬ 
injection to ensure adequate time for channel protein expression. Experiments were 
conducted at room temperature, 20-22°C. All oocytes were maintained in 0.01 K+ or 0.1 
K+ bath solution prior to the start of each experiment. For each experiment, micropipettes 
(Kimax-51, Kimble Products) with typical resistances of 0.5-1.5 MO were used. 
Resistances were checked prior to each experiment and no set of micropipettes was used 
for more than three consecutive experiments. 
For experiments where ROMK1 (Kiri.la) or ROMK2 (Kiri.lb) where expressed 
alone, oocytes were preincubated in 0.01 K+ bath solution for 10 minutes. Initial baseline 
current readings were obtained in this bath solution. Following impalement of the oocyte 
with both microelectrodes, the resting membrane potential was measured prior to clamping 
the membrane at a specified holding potential (typically -65mV). The experimental protocol 
consisted of current-voltage measurements (a trial) recorded at 60 second intervals in 
various bath solutions. Each trial consisted of as series of 20ms test pulses starting at - 
lOOmV increasing in 20mV increments up to a final voltage of +40mV or -1-lOOmV. The 
protocol began with a 5 minute equilibration period in 0.01 K+ bath solution followed by a 
14 minute test of sulfonylurea (glibenclamide) sensitivity. After assessing the response to 
glibenclamide, barium chloride (2mM) was then added to the bath solution for 2 minutes to 
determine the extent to which the current was dependent upon potassium movement. A 
final 5 minute recovery period in 0.01 K+ bath solution concluded the experiment. 
For experiments in ROMK1 (Kirl.la)-CFTR and ROMK2 (Kirl.lb)-CFTR 
coexpressed oocytes, the above protocol was also used. 
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For experiments in ROMK1-SUR and ROMK2 (Kirl.lb)-SUR coexpressed 
oocytes, the protocol was modified as follows. During set-up of the voltage clamp, the 
oocytes were transferred out of the Ca2+-plus ND96 storage media into 0.1 K+ or 0.5 K+ 
bath solution for approximately 3 to 5 minutes to allow the oocyte to re-equilibrate in the 
lower potassium solution. The protocol consisted of 5 minutes in 0.1 K+ or 0.5 K+ bath 
solution followed by 5 to 7 minutes in lOOpM or 250pM glibenclamide, 5 minutes 
recovery period in 0.1 K+ or 0.5 K+ bath solution, 2 to 3 minutes in 2mM barium chloride, 
and a final wash in 0.1 K+ or 0.5 K+ bath solution. 
Control experiments in uninjected oocytes were subject to the same protocols as 
described above. 
3-4.3. Protocol for BIR-Coinjected Oocytes 
Two-electrode voltage clamp experiments measuring whole-cell currents and 
response to sulfonylureas were performed on Xenopus oocytes injected with BIR (Kir6.2) 
alone, SUR1 alone, BIR (Kir6.2) plus SUR1, and A9 (BIR/Kir6.2 mutant) plus SUR1. 
Conditions for experiments were as above (Section 3-4.2). 
Experiments were initially performed on oocytes injected with BIR (Kir6.2) alone. 
BIR (Kir6.2) is postulated to be the pore subunit of the pancreatic beta cell KATP channel. 
To assess the level of channel activity present when expressed alone experiments were 
done exposing the oocyte first to standard ND96 (2mM KC1) bath solution then to High K+ 
(90mM KC1) bath solution. As we did not expect variations in the intracellular ATP 
concentration to result in BIR (Kir6.2) activation, no preliminary experiments with sodium 
azide were done. 
Next, to confirm that SUR1 expressed alone would not result in potassium current 
and to assess if SUR1 could couple with any endogenous oocyte channels, experiments 
were done exposing the oocyte first to standard ND96 (2mM KC1) bath solution then to 
High K+ (90mM KC1) bath solution. As a member of the ABC transporter superfamily, 
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SUR1 is responsive to changes in intracellular ATP concentrations. To assess if sodium 
azide metabolic inhibition of the oocyte would cause channel activation, experiments were 
done exposing the oocyte for 5 minutes to High K+ bath solution then 15 minutes to 3mM 
sodium azide. 
Lastly, we examined oocytes coexpressing BIR (Kir6.2)-SUR1. The protocol for 
these coinjected oocytes was 7 minutes in High K+ bath solution followed by 16 to 17 
minutes in High K+ bath solution plus 340pM diazoxide and 5mM sodium azide. 
For oocytes coinjected with SUR1 and the BIR (Kir6.2) mutant A9, the protocol 
used was 3 minutes in High K+ bath solution followed by 15 minutes in High K+ bath 
solution plus 340pM diazoxide and 5mM sodium azide. To assess if duration of exposure 
to diazoxide and sodium azide was adequate preincubation experiments were done as well. 
The protocol for these experiments consisted of 5 to 10 minutes of preincubation in High 
K+ bath solution plus 340pM diazoxide and 5mM sodium azide followed by 10 minutes of 
current-voltage measurements recorded at 60 second intervals in the same bath solution. 
As for the experiments described above, each trial consisted of 20ms test pulses starting at - 
lOOmV increasing in 20mV increments up to +40mV or +100mV. 
Solutions and Chemicals 
Ca2+-plus ND96 Solution: 96mM NaCl, 2mM KC1, 1.8mM CaCl2, ImM MgCl2, 5mM Hepes 
Ca2+-free ND96 Solution: 82.5mM NaCl, 2mM KC1, 1.8mM MgCb, 5mM Hepes 
Standard (ND96) Bath Solution: 96mM NaCl, 2mM KC1, 1.8mM CaCl2, ImM MgCl2, 5mM Hepes 
High K+ Bath Solution: 90mM KC1, ImM MgCl2, 1.8mM CaCl2, 5mM Hepes 
0 K+ Bath Solution: 105mM NaCl, ImM CaCl2, ImM MgCl2, 5mM Hepes 
0.01 K+ Bath Solution: Prepared by addition of 0.33pl of 3M KC1 per 100ml of 0 K+ Bath Solution 
0.1 K+ Bath Solution: 105mM NaCl, 0.ImM KC1, ImM CaCl2, ImM MgCl2, 5mM Hepes 
0.5 K+ Bath Solution: 105mM NaCl, 0.5mM KC1, ImM CaCl2, ImM MgCl2, 5mM Hepes 
Pipette Solution: 3M KC1 
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LB plates were made from lOg Bacto-Tryptone, 5g yeast extract, 5g NaCl, 2ml of 2N NaOH, 15g 
Bacto-Agar, and nano-H20 to 1000 ml. This mixture was autoclaved and cooled to approximately 40°C 
prior to the addition of ampicillin (lOOpg/ml) and then poured into plates. LB buffer was made from lOg 
Bacto-Tryptone, 5g yeast extract, 5g NaCl, 1ml of 1M MgS04, 10 ml of 1M Tris. and nano-H20 to 1000 
ml. This mixture was autoclaved prior to storage at 4°C. Ampicillin stock (lOOmg/ml) was made in 
sterile RNase-free dH20 and stored at -20°C until needed for LB-ampicillin plates or for bacterial growups. 
Glibenclamide (sulfonylurea) was dissolved in a 2:1 (vol.) ethanokdimethyl sulfoxide (DMSO) mixture 
to make a 0.001M or 0.1M stock solution. The stock solution was stored at 4°C. A lOOnM, lOOpM, or 
0.5mM working solution was made as needed for experiments; any remaining working solution was 
discarded after the second day of experiments. Glibenclamide was obtained from Sigma. 
Barium chloride was dissolved in 0 K+ bath solution to make a 0.1M stock solution . The stock 
solution was stored at 4°C. A 2mM or 5mM working solution was made as needed for experiments; any 
remaining working solution was discarded after two weeks of experiments. Barium chloride was obtained 
from Sigma. 
Diazoxide was dissolved in standard bath solution to make a 68mM stock solution . The stock 
solution was stored at 4°C. A 340pM working solution (Gribble et ah, 1997) was made as needed for 
experiments; any remaining working solution was discarded at the end of each day. Diazoxide was obtained 
from Sigma. 
Sodium azide was dissolved in standard bath solution to make a 3M stock solution . The stock 
solution was stored at 4°C. A 3mM or 5mM working solution was made as needed for experiments; any 
remaining working solution was discarded at the end of each day. Sodium azide was obtained from Sigma. 
The pH of each solution was adjusted to 7.4 with the exception of the diazoxide and sodium azide 
solution which was adjusted to a range of 7.4 to 7.6 as the diazoxide is insoluble in water but soluble in 
alkaline solutions. 
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3-5. Criteria for Inclusion of ROMK Injected Oocytes in Data Analysis Set 
Oocytes were evaluated for level of channel expression. If initial baseline currents 
were less than 500nA, the experiment was excluded for poor expression. An exception 
was made for oocytes injected with 0.03pg/pl of mRNA; current readings of less than 
500nA were accepted because of the low mRNA concentration. Only oocytes which 
maintained a stable baseline during the first 5 to 7 minutes in control bath solution were 
included in our study. A stable baseline was defined as a variation in current measurements 
of less than 10 percent for the entire 5 to 7 minute period. If the oocyte met the above 
criteria, an average baseline current was calculated over a 2 minute interval. To assess 
KATP sensitivity, an average current was also calculated over a 2 minute interval for an 
end-glibenclamide current reading. The percent inhibition by glibenclamide was calculated 
from the change in current ( IMbaseline-Iend_glibencam]de) over total current. Total potassium 
current was calculated from glibenclamide-sensitive and barium-sensitive currents. 
3-6. Statistical Analysis 
To determine the statistical significance of observed differences in the glibenclamide 
sensitivity of the ROMK channels when expressed alone or in the presence of an ABC 
transporter, we employed both the student t-test and the Kruskal-Wallis one way analysis 
of variance on ranks (ANOVA). The student t-test was employed when comparing two 
experimental groups. The ANOVA was employed when comparing among greater than 
two experimental groups. 
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4. Results 
4-1. ROMK Injected Oocytes 
4-1.1. ROMK2-Coinjected Oocytes 
We postulate that direct interactions between KATP channels and ABC transporters 
are the mechanism by which ABC transporters serve as regulators of channel activity. 
Therefore, changes in the structure of either the channel protein or the ABC transporter 
would be expected to impact upon their ability to couple and upon channel activity. 
Previously we have identified that an intact first nucleotide-binding fold (NBF) is necessary 
for the interaction between CFTR and ROMK2 (Kiri.lb). If, in fact, it is true that these 
protein-protein interactions are dependent upon a domain common to all ABC transporters, 
such as the NBF, then wild-type SUR1 with intact NBFs should be able to couple with 
ROMK2 (Kiri.lb) and confer sulfonylurea sensitivity. To examine this hypothesis, we 
conducted two-electrode voltage clamp experiments on Xenopus oocytes injected with 
ROMK2 (Kiri.lb) alone, ROMK2 (Kirl.lb)-CFTR, and ROMO (Kirl.lb)-SURl to 
assess sulfonylurea sensitivity of the KATP channel alone and in the presence of an ABC 
transporter. Resting baseline currents were measured during the 5 to 7 minute equilibration 
period in control 0.01K+ bath solution. The final experimental protocol consisted of this 
equilibration period followed by a 14 to 15 minute exposure to 500pM glibenclamide, a 2 
to 3 minute exposure to 2mM barium chloride to assess total potassium current, and a final 
5 minute recovery period in control bath solution. For some of the ROMK2 (Kirl.lb)- 
SUR1 injected oocytes (n=3), an alternate protocol was used initially. In this protocol, 
oocytes had a 5 minute equilibration period in a control 0.1 K+ bath, a 7 minute exposure to 
lOOpM glibenclamide, a 5 minute wash in control bath, a 2 minute exposure to 2mM 
barium chloride, and finally a 5 minute recovery in control bath. These initial experiments 
demonstrated that the effects of glibenclamide inhibition continued into the wash period. 
As a result the protocol was modified; the glibenclamide concentration was increased, the 
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time of exposure to glibenclamide was increased, and the post-glibenclamide wash period 
was eliminated. 
Table 3 and Figure 7 summarize the data from oocytes injected with ROMK2 
(Kiri.lb) alone, ROMK2 (Kiri.lb)-CFTR and ROMK2 (Kirl.lb)-SURl. The potassium 
currents observed in oocytes injected with ROMK2 (Kiri.lb) alone (n=ll) decreased by 
23.1 ±6.1% inhibition after exposure to glibenclamide. In contrast, the similar currents in 
oocytes expressing ROMK2 (Kiri.lb) with either ABC transporter showed significantly 
increased glibenclamide sensitivity (p=0.01). Coexpression of ROMK2 (Kiri.lb)-CFTR 
(n=l 1) and ROMK2 (Kirl.lb)-SURl (n= 13) resulted in 54.8± 10.8% and 56.5±6.7% 
decrease in potassium current in the presence of glibenclamide inhibition, respectively. 
This data supports the hypothesis that both of these ABC transporters with intact NBFs 
were able to interact with ROMK2 (Kir 1.1b) resulting in an enhanced sensitivity to 
glibenclamide. In addition, the difference in glibenclamide inhibition between ROMK2 
(Kirl.lb)-CFTR and ROMK2 (Kiri,lb)-SURl was not found to be statistically significant 
(p=0.89). 
Figure 8 depicts a representative time-course for an experiment in an oocyte 
expressing ROMK2 (Kirl.lb)-SURl as well as individual current-voltage traces at time 
points throughout the experiment. 
4-1.2. ROMK1-Coinjected Oocytes 
Having determined that the NBF1 of ABC transporters is involved in protein- 
protein interactions with ROMK2 (Kiri.lb), we directed our attention to the “associated” 
Katp channel itself. To examine if there are domains within the KATP channel itself 
important for coupling to occur, we studied N-terminus modifications in ROMK. Two- 
electrode voltage clamp experiments were conducted on Xenopus oocytes injected with 
ROMK1 (Kiri.la) alone, ROMK1 (Kirl.la)-CFTR, and ROMK1 (Kirl.la)-SURl to 
determine if there was any change in sulfonylurea sensitivity when the KATP channel was 
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expressed alone versus in the presence of an ABC transporter. The protocol for these 
oocytes was as described above. Again, the alternate protocol was used initially for a few 
of the ROMK1-SUR1 coinjected oocytes (n=2). 
Table 3 and Figure 9 summarize the data from oocytes injected with ROMK1 
(Kiri.la) alone, ROMK1 (Kirl.la)-CFTR and ROMK1 (Kirl.la)-SURl. Oocytes 
injected with ROMK1 (Kir 1.1 a) alone (n=8) demonstrated mild to moderate inhibition 
(28±2.8%) of potassium currents after exposure to glibenclamide. Oocytes injected with 
ROMK1 (Kirl.la)-SURl (n=6) demonstrated a similar degree of glibenclamide inhibition 
(24.6±6.3%, p=0.6) suggesting that coexpression of these two subunits did not result in 
an interaction capable of altering the sulfonylurea sensitivity. These findings can be 
contrasted to those from oocytes coexpressing ROMK2 (KiiT.lb)-SURl where there is an 
enhanced sulfonylurea sensitivity. Interestingly, in oocytes injected with ROMK1 
(Kirl.la)-CFTR (n=6) the currents were significantly less sensitive to glibenclamide, with 
only of 6±0.02% (p=0.009) inhibition of the total potassium current when compared to 
either ROMK1 (Kiri, la) alone or ROMK1 (Kirl.la)-SURl potassium currents. 
4-2. BIR Injected Oocytes 
To examine the normal coupling interactions of SUR1 and BIR (Kir6.2) and the 
effects of mutations in the M2 region of the channel pore upon this interaction, experiments 
were performed on oocytes expressing BIR (Kir6.2)-SUR1, A9 (a BIR/Kir6.2 mutant)- 
SUR1, as well as SUR1 and BIR (Kir6.2) alone. 
4-2.1. Expression of BIR and SUR1 Alone 
BIR (Kir6.2) is postulated to be the pore subunit of the pancreatic beta cell KATP 
channel. Two-electrode voltage clamp experiments were initially performed on Xenopus 
oocytes injected with BIR (Kir6.2) alone (n=3/5) to determine if this subunit resulted in 
channel activity. These oocytes were placed in bath solutions with varying potassium 
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concentrations and channel activity was measured. Current recordings were made in 
standard ND96 (2mM KC1) bath solution then High K+ (90mM KC1) bath solution. When 
placed in the High K+ bath, oocytes demonstrated a slight increase in potassium current as 
would be expected from the greater electrochemical potassium gradient. However, this 
change in potassium current was similar to those measured in uninjected oocytes (n=8) or 
H20-injected oocytes (n=5). These results suggested that the BIR (Kir6.2) subunit 
expressed alone did not result in a functional potassium channel. 
Next we turned our attention to SUR1 which is postulated to be the regulatory 
subunit and ATP sensor of the pancreatic beta cell KATP channel. We repeated the above 
protocol in oocytes expressing SUR1 alone (n=5) to confirm that SUR1 was not a 
potassium channel itself and to determine if SUR1 would couple with an endogenous Kjr 
channel. Potassium currents were found to be similar to those measured in uninjected 
oocytes in these experiments as well. As a member of the ABC transporter superfamily, 
SUR1 possesses two NBFs allowing it to be responsive to changes in intracellular ATP 
concentrations. To assess if sodium azide metabolic inhibition of the oocyte would cause 
channel activation, experiments were done exposing the SUR1-injected oocytes (n=3) to 
High K+ bath solution for 5 minutes then to 3mM sodium azide for 15 minutes. Under 
these experimental conditions, oocytes injected with SUR1 alone did not demonstrate an 
appreciable increase in potassium currents. 
The result of our experiments in oocytes expressing BIR (Kir6.2) or SUR1 alone 
confirmed those reported by Gribble et al. demonstrating that coexpression of both 
subunits was necessary to reconstitute KATP currents. 
4-2.2. Coexpression of BIR and SUR1 
To assess the normal coupling of both KATP channel subunits, we examined oocytes 
coexpressing BIR (Kir6.2)-SUR1. In these experiments we exposed the coinjected 
oocytes to a High K+ solution followed by a High K+ solution plus 340pM diazoxide and 
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5mM sodium azide. Treatment with diazoxide and sodium azide resulted in potassium 
currents significantly greater than measured in High K+ solution alone. We were able to 
demonstrate this in 2 oocytes confirming the results reported by Gribble et al. However, 
we experienced some difficulty in repeating this result consistently. Whether this reflects 
problems with the Xenopus oocyte as a reliable expression system or is an issue with the 
quality of the mRNA has not been determined. In the oocytes that did express, however, 
the average currents measured at -lOOmV were approximately -8 to -40pA which are 
similar to those previously reported (Gribble et al., 1997). 
4-2.3. Coexpression of a BIR mutant and SUR1 
Having confirmed that the Xenopus oocyte expression system was adequate for 
studying interactions between BIR (Kir6.2) and SUR1 we examined oocytes coinjected 
with a BIR/Kir6.2 mutant (A9) and SUR1. Our goal was to determine if potassium 
currents could be stimulated in these oocytes. Oocytes were equilibrated for 3 minutes in 
High K+ bath solution then exposed to High K+ bath solution plus 340pM diazoxide and 
5mM sodium azide for 15 minutes. No change in potassium current was observed (n=2). 
To assess if duration of exposure to diazoxide and sodium azide was adequate, 
preincubation experiments were done as well. The protocol for these experiments 
consisted of 5 to 10 minutes of preincubation in High K+ bath solution plus 340pM 
diazoxide and 5mM sodium azide followed by 10 minutes of current-voltage measurements 
recorded at 60 second intervals in the same bath solution. Again, no change in potassium 
current was observed (n=5). These preliminary findings appear to suggest that 
coexpression of the BIR (Kir6.2) mutant A9 with SUR1 does not result in a functional 
Katp channel and that altering the M2 region of the channel pore leads to a dysfunctional 
channel. 
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5. Discussion 
5-1. Effects of Mutations in CFTR upon Interactions with ROMK2 
A recent study by McNicholas et al. suggested that mutations in specific domains of 
CFTR—the first nucleotide-binding fold (NBF1)—interfere with CFTR’s ability to interact 
with the ROMK2 (Kiri. lb) channel (McNicholas et al., 1997). In that study glibenclamide 
was shown to inhibit 56% of potassium current in oocytes expressing both ROMK2 
(Kiri.lb) and CFTR. In contrast, there was only 11% inhibition of potassium currents in 
oocytes expressing ROMK2 (Kiri.lb) alone. Furthermore, when ROMK2 (Kir 1.1b) was 
expressed with CFTR constructs containing mutations in the first nucleotide-binding fold 
(NBF1), there was no enhancement of glibenclamide sensitivity suggesting that an intact 
NBF1 is necessary for this interaction. Supporting this hypothesis, oocytes injected with 
ROMK2 (Kiri.lb) and a truncated CFTR construct containing an intact NBF1 still 
exhibited enhanced (46%) glibenclamide sensitivity. In contrast, when ROMK2 (Kir 1.1b) 
was coexpressed with a truncated CFTR construct lacking NBF1 only 12% inhibition 
remained. Given that NBFs are motifs common to ABC transporters these data suggest 
that certain family members may be able to substitutes for other members. 
5-2. Ability of SlJRl to Substitute for CFTR in Interactions with ROMK2 
Pursuing this theory further, we wondered if SURl could substitute in the ROMK2 
(Kirl.lb)-CFTR interaction. Studying SURl’s ability to substitute for CFTR in its 
interactions with the ROMK family of channel proteins offered the opportunity to examine 
similarities and differences in the domain organization of these two ABC transporters 
(Figure 10). In our studies, oocytes coexpressing either ROMK2 (Kiri.lb)-CFTR or 
ROMK2 (Kirl.lb)-SURl demonstrated enhanced sensitivity to sulfonylureas when 
compare to ROMK2 (Kiri.lb) alone. In addition, when compared between themselves, 
the degree to which these two ABC transporters were able to enhance glibenclamide 
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sensitivity was not statistically significant. These data not only demonstrate that it may be 
possible for one family member to substitute for another and provide similar regulatory 
function but also suggest that similarities exist in how CFTR and SUR1 interact with 
ROMK2 (Kiri.lb). Furthermore, it implicates the NBF as an essential component for this 
interaction. As the NBF is the region of the protein that binds ATP, one can speculate that 
this interaction may be altered by energy dependent processes such as phosphorylation- 
dephosphorylation. Additional studies focusing upon these questions will need to be done. 
5-3. Effects of Alterations in ROMK upon Interactions with CFTR 
Clearly changes in the ABC transporter impact upon its ability to interact with 
heterologous channel proteins. If, as we postulated, the relationship between ABC 
transporters and channels are dynamic involving direct protein-protein interactions, we 
would expect that changes in the channel itself would also effect these interactions. 
Specifically, we postulated that changes in the cytoplasmic N-terminus of ROMK would 
alter its interaction with CFTR. Our choice to study the N-terminus was based upon 
studies by Tinker et al. and Tucker et al. Tinker et al. suggested that assembly of a 
functional multimeric Kir channel is dependent upon compatibility of the proximal C- 
terminus and the M2 region (Tinker et al., 1997). Tucker et al. demonstrated that BIR 
(Kir6.2) mutants with C-terminus deletions expressed channel activity when injected alone 
into Xenopus oocytes while those with N-terminus deletions did not express channel 
activity, suggesting that the C-terminus may inhibit channel activity by blocking the pore 
(Tucker et al., 1997). When the C-terminus truncated forms of BIR (Kir6.2) were 
coexpressed with SUR1, Tucker et al. found enhancement of ATP sensitivity as well as 
restoration of the effects of diazoxide, tolbutamide, and Mg-ADP, suggesting that SUR1 
coupling is not affected by the C-terminus deletions. In addition, studies (Tinker et al., 
1997) have shown the N-terminus and Ml region to be important in the assembly of 
functional multimeric voltage-gated potassium channels, suggesting that the N-terminus is 
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capable of playing a role in protein-protein interactions. Our studies, as described earlier, 
had confirmed that a ROMK2 (Kirl.lb)-CFTR interaction exists. To examine if 
alterations in the N-terminus of ROMK2 (Kiri.lb) would impact upon CFTR’s ability to 
increase inhibition of ROMK2 (Kiri.lb) by glibenclamide, we studied another isoform of 
the ROMK channel, ROMK1 (Kir 1.1 a) whose N-terminus had an additional 19 amino 
acids (Figure 11). Both isoforms, ROMK1 (Kiri.la) and ROMK2 (Kiri.lb), express 
functional Kir channels when expressed alone. We found that oocytes expressing ROMK1 
(Kirl.la)-CFTR did not exhibit the enhanced glibenclamide sensitivity we had seen in 
oocytes expressing ROMK2 (Kiri.lb)-CFTR. In fact, there was a statistically significant 
decrease in glibenclamide inhibition of the potassium current as compared to oocytes with 
ROMK1 (Kiri.la) alone, suggesting that there was an antagonistic effect on glibenclamide 
sensitivity. There are a number of possible explanations for the decrease in sensitivity. 
One possible explanation is that there was no coupling between CFTR and ROMK1 
(Kiri.la) and that the decreased effect of glibenclamide, although statistically significant, is 
not physiologically relevant. Another explanation may be that some coupling of the two 
subunits occurs which interferes with sulfonylurea inhibition of channel activity. Further 
studies will need to be done to address this issue. However, these data suggest that 
alterations in the N-terminus of the Kir channel subunit also effect the ABC transporter- 
channel protein interaction. 
5-4. Effects of Alterations in ROMK upon Interactions with SUR1 
To assess if the ROMK1 (Kirl.la)-CFTR findings describe a real interaction with 
inhibitory effects upon glibenclamide sensitivity or reflect a lack of coupling between the 
two subunits, we examined another ABC transporter, SURl. In oocytes coexpressing 
ROMK1 (Kirl.la)-SURl, there was neither increase nor decrease of glibenclamide 
inhibition compared to ROMK1 (Kir 1.1 a) alone suggesting that no interaction occurred. 
The simplest explanation of this finding is that the results observed with ROMK1 

38 
(Kirl.la)-CFTR represent a non-interactive state as well and that statistical significance 
was a function of the statistical analysis. 
If one examines ROMK1 (Kiri.la) versus ROMK2 (Kiri, lb), the 19 amino acid 
difference is in an region that has been shown to have a number of PKC sites. Thus, the 
alteration in the interaction may be dependent on a number of factors: changes in PKC 
activity, specifically the phosphorylation or dephosphorylation states of the channel, and/or 
conformational changes. Further studies will need to be done. 
5-5. Effect of a Mutation in BIR upon Interactions with SUR1 
Previous studies have shown that mutations within the SUR1 subunit have resulted 
in cases of PHHI, presumably through decreased KATP channel activity and subsequent 
oversecretion of insulin (Thomas et al., 1995; Aguilar-Bryan and Bryan, 1996; Kane et al., 
1996; Thomas et al., 1996; Dunne et al., 1997). Specifically, mutations in NBF2 and 
NBF1 have been implicated. As SUR1 with its NBFs is believed to be responsible for 
sensing ATP levels within the pancreatic beta cell, mutations affecting the interaction 
between the NBF and ATP could result in the clinical features of PHHI. BIR (Kir6.2) is 
believed to be the predominant pore-forming subunit of the pancreatic beta cell KATP 
channel. However, BIR (Kir6.2) expressed alone within the Xenopus oocyte expression 
system does not produce KATP channel currents and appears to be inactive. A recent study 
by Thomas et al. reported a mutation in BIR (Kir6.2) which is predicted to disrupt the 
second transmembrane domain of the KIR channel. This mutation was found in a child 
affected with PHHI, with clinical features that did not appear to differ from cases where the 
mutation was found to be present in SURF In our study we examined yet another BIR 
(Kir6.2) mutant, A9, which is postulated to produce a mutation of the M2 region of BIR 
(Kir6.2). 
In our study we were able to replicate in the Xenopus oocyte expression system 
some of the results reported in 1997 by Gribble et al. Expression of either BIR (Kir6.2) or 
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SUR1 alone did not reconstitute KATP currents. In two oocytes coexpressing B1R (Kir6.2) 
and SUR1 we were able to demonstrate reconstitution of this current when stimulated with 
diazoxide and sodium azide. When oocytes coexpressing the BIR (Kir6.2) mutant A9 and 
SUR1 were measured, current readings were similar to those of uninjected or H,0-injected 
oocytes. This suggested that the interaction between the BIR (Kir6.2) and SUR1 subunits 
was somehow disrupted as a result of the mutation in A9. 
As the interaction between SUR1 and BIR (Kir6.2) is still unclear there are a 
number of mechanisms by which this disruption could occur. Our hypothesis was that 
direct interactions are responsible for SURl’s regulation of BIR (Kir6.2) and that 
mutations affecting the ability of the two subunits to interact would result in KATP 
dysfunction and the presentation of PHHI. It is also possible that the A9 mutation alters 
the processing of the Kir subunit making it less available to interact with SUR1. Since the 
stoichiometry of the relationship between SUR1 and BIR (Kir6.2) in order for 
reconstitution of a function KATP channel also has not been elucidated this is an area that 
needs further investigation. 
Alternatively, a recent study by Shyng et al. examined the effect of mutations of 
pore-lining residues upon stability of the open channel and suggested that structural 
changes within the BIR (Kir6.2) subunit may impact upon ATP-sensitivity of the channel 
(Shyng et al., 1997). Another mechanism by which mutations in BIR (Kir6.2) may result 
in an inactive KATP channel is through alterations in either the conformation or structure of 
the pore-lining residues. 
5-6. Clinical Implications 
As defects in ion channels and transporters are responsible for numerous human 
diseases, elucidation of their role in pathophysiology constitutes the first step in improving 
clinical management and developing therapeutic interventions. The ABC transporter 
superfamily of proteins has been implicated in a wide range of human diseases (Table 1), 
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such as CF and PHHI. Consequently, determination of the structure-function relationship 
of ABC transporters with regard to their intrinsic channel/transporter activity as well as 
their regulation of heterologous channels may provide insights into disease process which 
can be translated into alternative targets for therapy. Of particular interest is the ability of 
some ABC transporters to substitute for other members of the superfamily and perhaps to 
couple with multiple ion channels. Our initial studies suggest that this is due to the 
presence of specific motifs of ABC transporters, such as the NBFs. Mutations in the 
NBFs in CFTR and SUR1 have been associated with clinical CF and PHHL 
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Figure 1. The Typical ABC Transporter. This is a schematic representation of a 
typical ABC transporter with its four core domains. The two nucleotide-binding domains 
are represented by the cross-hatched areas. The transmembrane domains are depicted here 
with six alpha-helical segments with the N- and C-termini on the cytoplasmic face. 
Although these domains are pictured as separate polypeptides here, they may also be fused 
to form a multidomain protein. The * designates the cytoplasmic loop which contains a 
short sequence motif conserved between many ABC transporters. Adapted from Higgins, 
1992. 
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Figure 2. Mechanisms of Channel Regulation. 
1. The substrate (X) transported by the ABC transporter acts to modulate channel activity 
in an autocrine fashion. 
2. The ABC transporter acts directly upon the channel protein. 
3. The ABC transporter facilitates increased insertion of the channel protein into the 
membrane. 
4. The ABC transporter regulates the channel protein via an intermediate protein molecule. 
Adapted from Higgins, 1995. 
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Figure 3. Model of the Cystic Fibrosis Transmembrane Conductance 
Regulator. This schematic illustration shows the atypical five domain structure of CFTR 
containing not only two transmembrane domains and two nucleotide-binding domains, but 
also as additional regulatory (R) domain. 
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Figure 4. Ion Channels Involved in Regulation of Respiratory Airway 
Secretions. Chloride enters the cell across the basolateral membrane coupled to sodium 
movement out of the cell. This cotransport process may involve either a Na7Cf 
cotransporter or a Na7K72Cl" cotransporter. The chloride then moves out of the cell 
through chloride channels on the apical membrane. This net movement of chloride is 
driven by the presence of the basolateral Na7K+ pump, the basolateral potassium channel, 
and the apical sodium channel. 
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Figure 5. Proposed Model of the Pancreatic Beta Cell KATP Channel. The 
pancreatic beta cell KATP channel is postulated to be a complex of SUR1 and BIR (Kir6.2). 
Although we represent this relationship as one to one, the actual stoichiometry of this 
complex is unknown. 
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Figure 6. Glucose Homeostasis and Insulin Secretion. This figure illustrates the 
pathway for insulin secretion in the pancreatic beta cell. The pancreatic KATP channel 
(represented here as the SUR1 and BIR/Kir6.2 complex) maintains the resting membrane 
potential for the cell. An increase in the glucose concentration results in closure of the KATP 
channel. Depolarization of the cell activates the voltage-dependent calcium channels. The 
influx of calcium ions triggers exocytosis and insulin release. Sulfonylureas function by 
blocking the KATP channel and causing depolarization of the cell membrane. 
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Figure 7. Glibenclamide Sensitivity of ROMK2 Currents. This figure is a 
summary of the data obtained for ROMK2 expressed alone, or with CFTR or SUR1 as 
indicated on the X-axis. 
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Control Glibenclamide Barium Chloride Wash 
Figure 8. Time-Course and Individual Current-Voltage Traces. This is a 
representative time-course for an experiment in oocytes injected with ROMK2-SUR1. The 
individual current-voltage traces were taken at various points throughout the experiment. 
The protocol was as follows: 5 minutes control —» 13 minutes in glibenclamide —» 3 
minutes in barium chloride —>• 5 minutes wash. 
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Glibencamide sensitivity of ROMK1 currents 
Figure 9. Glibenclamide Sensitivity of ROMK1 Currents. This figure is a 
summary of the data obtained for ROMK1 expressed alone, or with CFTR or SUR1 as 
indicated on the X-axis. 
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Figure 10. Comparison of Structure of CFTR and SURL Although CFTR and 
SUR1 are both members of the ABC transporter superfamily, each is a somewhat atypical 
example. Of note, CFTR has an additional regulatory (R) domain. SUR1 has a nine 
alpha-helical N-terminus transmembrane domain and a four alpha-helical C-terminus 
transmembrane domain. In addition, SURl’s N-terminus is extracellular while most ABC 
transporters, including CFTR, have a cytoplasmic N-terminus. 
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Figure 11. Isoforms of the ROMK Renal KATP Channel. This figure illustrates 
the general structure of the Kir family of potassium channels to which the ROMK channel 
belongs. ROMK1 (Kiri.la) and ROMK2 (Kir 1.1b) are two isoforms that differ in their 
N-terminus by 19 amino acids but are otherwise identical. The amino acid sequence of 
their N-termini are aligned above. 
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ABC Transporter Association with Human Disease 
ABCR Stargardt macular dystrophy1 
ALD adrenoleukodystrophy2 
CDR1 drug resistant candidosis3 
CFTR cystic fibrosis3'4 
EhPgpl drug resistant amoebiasis3 
IdMDR drug resistant visceral leishmaniasis3 
pfMDR2 drug resistant malaria3 
P-glycoprotein (MDR1) multidrug resistance (cancer chemotherapy)5 
PMP70 Zellweger syndrome6 
SMDR2 drug resistant schistosomiasis3 
SUR1 persistent hyperinsulinemic hypoglycemia of infancy7'8, non-insulin 
dependent diabetes mellitus9 
TAPI Behcet’s disease10, multiple sclerosis" 
TAP2 bare lymphocyte syndrome type l3, multiple sclerosis" 
VgA drug resistant wound infections, pneumonia, impetigo3 
Table 1. ABC Transporters and Associated Diseases. These are some examples 
of human diseases associated with ABC transporters. 
'Allikmets et al., 1997; 2Mosser et al., 1993; 3Decottignies and Goffeau, 1997; 4Riordan et al., 1989; 5Gill 
et al., 1992; 6Gartner et al., 1992; 7Bryan and Aguilar-Bryan, 1996; 8Thomas et al., 1995; yInoue et al., 
1996; "'Gonzalez-Escribano et al, 1995; "Middleton et al, 1994. 
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Class of Defect Examples Domain 
I. Protein production G542X NBD1 
3905 insT NBD2 
621 + G^T TMD1 
II. Protein processing/trafficking AF508 NBD1 
AI507 NBD1 
S549I NBD1 
S549R NBD1 
A559T NBD1 
N1303K NBD2 
III. Channel regulation/activation G551D NBD1 
G551S NBD1 
G1224E NBD2 
S1255P NBD2 
G1349D NBD2 
IV. Chloride conductance R117H TMD1 
R334W TMD1 
R347P TMD1 
Table 2. Classes of CFTR Mutations That Result in Cystic Fibrosis. CFTR 
mutations can be separated into four classes of defects. Some examples of these mutations 
and what domain they effect are listed above. NBD=nucleotide-binding domain, 
TMD=transmembrane domain. Adapted from Welsh, et ah, 1993. 
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Summary of Data in ROMK Injected Oocytes 
ROMK2 Injected Oocytes 
Construct % Inhibition P = n= 
ROMK2 23.1 ±6.1 — 11 
ROMK2-CFTR 54.8±10.8 0.02 11 
ROMK2-SUR1 56.5±6.7 0.001 13 
ROMK1 Injected Oocytes 
Construct % Inhibition P = n= 
ROMK1 28±2.8 — 8 
ROMK1-CFTR 6±0.02 0.00006 6 
ROMK1-SUR1 14.6±6.3 0.6 6 
Table 3. Summary of Data in ROMK Injected Oocytes. The percent inhibition 
is expressed as mean±SE. P values are based upon Student t-test. Comparison was made 
to ROMK2 or ROMK1 alone, as appropriate. 
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